OPTHF
Optimi Health Corp.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- Short sellersCOVERING
Short interest −50.0% to 8.6K shares. 1.0 days to cover.
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next Q | — | — | — | $0.00 |
| Current Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· May 15, 2026SecBot reports
4 filings · 0 bullish · 0 bearish · 4 neutral- NEUTRAL 6-KMay 26, 2026
Optimi Health Corp. announced completion of a production run of naturally derived psilocybin…
Monitor for future clinical trial results in Europe and any expansion of Australian reimbursement pathways, which could signal revenue inflection. The absence of serious adverse events in Australian…
- NEUTRAL F-1/AMay 19, 2026
Optimi Health Corp., a Canadian GMP-compliant psychedelic pharmaceutical manufacturer, filed…
The IPO's closing is contingent on Nasdaq listing approval and SEC effectiveness — watch for EFFECT notice and final pricing announcement. The offering provides a ~US$12.2M net lifeline to a company…
- NEUTRAL F-1/AApr 23, 2026
Optimi Health Corp., a Canadian psychedelic pharmaceutical company, is conducting its U.S. IPO by…
Monitor the next 10-Q filing for guidance on how the IPO proceeds will be allocated, particularly regarding scaling production and market expansion plans.
- NEUTRAL F-1/AApr 21, 2026
Optimi Health Corp., a Canadian psychedelic pharmaceutical company, is conducting its U.S. IPO by…
Monitor for the final prospectus and pricing announcement, as the offering price within the $6.00-$8.00 range will determine the actual capital raised and potential dilution. The success of the…
All OPTHF filing & press-release reports (4)
- 6-K reportMay 26, 2026
- F-1/A reportMay 19, 2026
- F-1/A reportApr 23, 2026
- F-1/A reportApr 21, 2026